Serina Therapeutics, Inc. (SER) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Serina Therapeutics reported revenue of $130,000, up 132.1% from $56,000 the year before. Net income was -$19.2M (a -14755.4% net margin), or -$1.91 per diluted share. Operating margin was -18478.5%. Operating activities generated -$18.0M of cash, leaving -$18.1M of free cash flow. At fiscal year end, Serina Therapeutics held $7.0M in total assets against $7.0M in total liabilities, including $3.1M of cash and equivalents.
Open the full interactive Serina Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Serina Therapeutics Key Stats
| Share Price | $1.82 |
|---|---|
| Market Cap | $29.8M |
| Revenue YoY Growth | +132.1% |
| 52-Week Range | $1.28 – $5.26 |
| Shares Outstanding | 16.4 million (basic, 2026 Q2) |
Serina Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | $144,000 | $34,000 | $142,000 | $56,000 | $130,000 |
| Gross Profit | $1.7M | $125,000 | $21,000 | $102,000 | — | — |
| Operating Income | -$10.7M | -$7.9M | -$7.0M | -$9.9M | -$17.0M | -$24.0M |
| Pre-Tax Income | -$11.1M | -$8.7M | $10.5M | $14.8M | -$11.1M | -$19.2M |
| Income Tax | -$150,000 | -$10,000 | $21.0M | $29.6M | $0 | $18,000 |
| Net Income | -$10.9M | -$8.7M | -$10.5M | -$14.8M | -$11.1M | -$19.2M |
| Diluted EPS | -$10.36 | -$8.21 | — | -$13.72 | -$1.51 | -$1.91 |
Serina Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$4.6M | -$3.3M | -$6.9M | -$6.4M |
| Diluted EPS | -$0.45 | -$0.33 | -$0.58 | -$0.55 |
Serina Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $527,000 | $584,000 | $645,000 | $345,000 | $3.7M | $3.1M |
| Current Assets | $2.3M | $2.2M | $2.5M | $754,000 | $5.7M | $6.1M |
| Total Assets | $3.9M | $3.2M | $3.2M | $12.0M | $6.7M | $7.0M |
| Current Liabilities | $5.4M | $9.0M | $10.1M | $5.9M | $2.4M | $3.6M |
| Total Long-Term Debt | — | — | $18.1M | $4.4M | — | $2.9M |
| Total Liabilities | $9.3M | $15.0M | $20.6M | $6.6M | $6.2M | $7.0M |
| Shareholders' Equity | -$5.1M | -$11.8M | -$17.2M | $5.5M | $641,000 | -$37,000 |
Serina Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$7.8M | -$7.9M | -$5.9M | -$7.8M | -$17.1M | -$18.0M |
| Cash From Investing | -$20,000 | $666,000 | — | -$10.0M | -$22,000 | -$59,000 |
| Cash From Financing | $6.0M | $7.2M | $6.0M | $17.5M | $13.2M | $17.4M |
| Free Cash Flow | -$7.8M | -$7.9M | — | — | -$17.1M | -$18.1M |
Figures from Serina Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Serina Therapeutics financials page for every line item.
Serina Therapeutics Company Profile
| Ticker | SER |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Huntsville, Alabama |
| Incorporated in | Alabama |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001708599 |
Frequently Asked Questions
What was Serina Therapeutics' revenue in fiscal 2025?
Serina Therapeutics (SER) reported revenue of $130,000 for fiscal 2025.
What is Serina Therapeutics' annual revenue history?
Serina Therapeutics' annual revenue by fiscal year: 2020: $1.9M; 2021: $144,000; 2022: $34,000; 2023: $142,000; 2024: $56,000; 2025: $130,000.
What was Serina Therapeutics' net income in fiscal 2025?
Serina Therapeutics reported net income of -$19.2M for fiscal 2025.
What was Serina Therapeutics' earnings per share (EPS) in fiscal 2025?
Serina Therapeutics' diluted EPS was -$1.91 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Serina Therapeutics generate in fiscal 2025?
Serina Therapeutics generated -$18.1M of free cash flow in fiscal 2025.
What was Serina Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Serina Therapeutics reported revenue of $0.
How much debt does Serina Therapeutics have?
Serina Therapeutics reported $2.9M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Serina Therapeutics are outstanding?
Serina Therapeutics reported a weighted average of 16.4 million basic shares outstanding in 2026 Q2.
What is Serina Therapeutics' market cap?
Based on its latest closing price, Serina Therapeutics (SER) has a market capitalization of about $29.8M.
When does Serina Therapeutics' fiscal year end?
Serina Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Serina Therapeutics headquartered?
Serina Therapeutics lists its business address in Huntsville, Alabama in its SEC filings.